It uses a novel dose escalation design to investigate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity in patients with advanced disease who have progressed on first-line BRAF/MEK inhibitors [32]. This evidence concerns the gene BRAF and neoplasm.